Heart International最新文献_第10页

Andexanet Alfa and its Clinical Application. Andexanet Alfa 及其临床应用。

IF 1.9

Heart International Pub Date : 2020-06-19 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.1.20

Fauve A Noordergraaf, Marco Alings

{"title":"Andexanet Alfa and its Clinical Application.","authors":"Fauve A Noordergraaf, Marco Alings","doi":"10.17925/HI.2020.14.1.20","DOIUrl":"10.17925/HI.2020.14.1.20","url":null,"abstract":"Factor Xa (FXa) inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation, and for the treatment and prevention of deep venous thrombosis and pulmonary embolism. Compared with warfarin, individual FXa inhibitors are associated with a lower risk of major bleeding. Nevertheless, bleeding remains a feared complication of any anticoagulant therapy. Despite their demonstrated safety, implementation of FXa inhibitors in clinical practice may have been limited by the lack of a specific antidote. Recently, however, the United States Food and Drug Administration and the European Medicines Agency approved andexanet alfa for reversal of anticoagulation in patients treated with rivaroxaban or apixaban who have life-threatening or uncontrolled bleeding. This review will discuss andexanet alfa's mode of action, indication for use and efficacy, with a focus on its appropriate use in clinical practice. Unnecessary usage should be prevented as this may compromise patient safety. Assessment of potentially suitable patients by a multidisciplinary team, use according to the institutional protocol and central storage, all contribute to proper use of andexanet alfa. A practical tool to direct appropriate use of andexanet alfa is proposed.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"14 1","pages":"20-23"},"PeriodicalIF":1.9,"publicationDate":"2020-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524750/pdf/heart-int-14-20.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40567772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Contemporary Drug-eluting Coronary Stents - Is Any Stent Better than the Others? 当代药物洗脱冠状动脉支架的比较——是否有一种支架比其他支架更好?

IF 0.2

Heart International Pub Date : 2020-06-18 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.1.34

William Parker, Javaid Iqbal

{"title":"Comparison of Contemporary Drug-eluting Coronary Stents - Is Any Stent Better than the Others?","authors":"William Parker, Javaid Iqbal","doi":"10.17925/HI.2020.14.1.34","DOIUrl":"https://doi.org/10.17925/HI.2020.14.1.34","url":null,"abstract":"Percutaneous coronary intervention (PCI) with implantation of a metallic drug-eluting stent (DES) is the mainstay of treatment in patients with significant coronary artery disease or acute coronary syndromes. DESs comprise a metallic platform and an anti-proliferative drug, usually released from a polymer coating. A wide range of DESs, differing in platform, polymer or drug, are currently available for clinical use. Although there are significant differences in the physical, biological and pharmacological properties of contemporary DESs, it remains unclear whether these impact meaningfully on clinical outcomes for patients undergoing PCI. Numerous randomised clinical trials have compared DESs in recent years, but these trials are typically designed to show non-inferiority, rather than superiority. Data from meta-analyses have helped to study this in larger populations, but have limitations. Improvement in stent design continues and ongoing work is exploring the effects of new innovations as well as gathering further data on existing devices. This review explores the development, properties and clinical efficacy of current-generation DESs, comparing different types where possible, whilst identifying areas of further work.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"14 1","pages":"34-42"},"PeriodicalIF":0.2,"publicationDate":"2020-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524693/pdf/heart-int-14-34.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40567773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

A Rare Case of Cor Triatriatum Sinister in Adulthood with Atypical Manifestation. 罕见的成年期三心房心绞痛，表现不典型。

IF 0.2

Heart International Pub Date : 2020-06-14 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.1.53

Thauler Alves de Oliveira, Renan Attílio Santos Marquiori

引用次数: 0

Management of Coronary Artery Disease in the Setting of Transcatheter Aortic Valve Replacement. 经导管主动脉瓣置换术中冠状动脉疾病的处理。

IF 0.2

Heart International Pub Date : 2020-04-15 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.1.24

Natraj Katta, J Dawn Abbott, Ankur Kalra, Fawaz Alenezi, Andrew Goldsweig, Herbert Aronow, Poonam Velagapudi

{"title":"Management of Coronary Artery Disease in the Setting of Transcatheter Aortic Valve Replacement.","authors":"Natraj Katta, J Dawn Abbott, Ankur Kalra, Fawaz Alenezi, Andrew Goldsweig, Herbert Aronow, Poonam Velagapudi","doi":"10.17925/HI.2020.14.1.24","DOIUrl":"https://doi.org/10.17925/HI.2020.14.1.24","url":null,"abstract":"Aortic stenosis and coronary artery disease (CAD) frequently co-exist, as they share a common pathophysiology and risk factors. Due to lack of randomised controlled trials (RCTs) and exclusion of significant CAD in transcatheter aortic valve replacement (TAVR) trials, the optimal method of revascularisation of CAD in patients undergoing TAVR remains unknown. Observational studies and meta-analyses have shown varied results in outcomes for patients with CAD undergoing TAVR, and no significant difference in post-TAVR outcomes in patients who underwent revascularisation either prior to or during TAVR versus those who did not. However, some observational studies have shown that patients with lower residual SYNTAX score (rSS) post-revascularisation have better outcomes post-TAVR compared to those with higher rSS. RCTs are needed to clearly understand whether revascularisation is beneficial in these patients. Until then, management of CAD in patients undergoing TAVR must be individualised based on discussion with the heart team.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"14 1","pages":"24-28"},"PeriodicalIF":0.2,"publicationDate":"2020-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524713/pdf/heart-int-14-24.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40583482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft in Left Main Revascularisation. 经皮冠状动脉介入治疗与冠状动脉旁路移植术在左主干血管重建中的应用。

IF 1.9

Heart International Pub Date : 2020-03-12 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.1.11

Timir Kumar Paul

引用次数: 0

New Consumer Guidance on Wearable Devices from the Consumer Electronics Show 2020. 2020年消费电子展关于可穿戴设备的新消费者指南。

IF 0.2

Heart International Pub Date : 2020-03-12 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.1.9

Nassir F Marrouche

引用次数: 0

Summary of Practice Considerations for Percutaneous Coronary Intervention of Left Main Bifurcation Disease. 左主干分叉疾病经皮冠状动脉介入治疗实践注意事项摘要。

IF 1.9

Heart International Pub Date : 2020-01-07 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.2.69

Tanveer Rab, J Dawn Abbott, Mir Babar Basir, Azeem Latib, Gautam Kumar, Perwaiz Meraj, Kevin Croce, Rajesh Davé

引用次数: 0

Letter from the Editor-in-Chief. 总编辑的来信。

IF 0.2

Heart International Pub Date : 2019-12-30 eCollection Date: 2019-01-01 DOI: 10.17925/HI.2019.13.2.9

Rajesh Davé

引用次数: 0

A Review of the Ultrathin Orsiro Biodegradable Polymer Drug-eluting Stent in the Treatment of Coronary Artery Disease. 超薄 Orsiro 生物可降解聚合物药物洗脱支架在冠状动脉疾病治疗中的应用综述。

IF 1.9

Heart International Pub Date : 2019-12-23 eCollection Date: 2019-01-01 DOI: 10.17925/HI.2019.13.2.17

James J Wu, Joshua Ah Way, David Brieger

{"title":"A Review of the Ultrathin Orsiro Biodegradable Polymer Drug-eluting Stent in the Treatment of Coronary Artery Disease.","authors":"James J Wu, Joshua Ah Way, David Brieger","doi":"10.17925/HI.2019.13.2.17","DOIUrl":"10.17925/HI.2019.13.2.17","url":null,"abstract":"Drug-eluting stents (DES) have revolutionised the treatment of coronary artery disease (CAD) in patients undergoing percutaneous coronary intervention. In recent years, there has been a focus on a new generation of DES, such as biodegradable polymer DES (BP-DES). This novel stent platform was developed with the hope of eliminating the risk of very late stent thrombosis associated with the current gold-standard durable polymer DES (DP-DES). Ultrathin Orsiro BP-DES (Biotronik, Bülach, Switzerland) are based on a cobalt-chromium stent platform that is coated with a bioresorbable polymer coating containing sirolimus. These devices have one of the thinnest struts available in the current market and have the theoretical benefit of reducing a chronic inflammatory response in the vessel wall. In 2019, the United States Food and Drug Administration (FDA) approved the use of Orsiro BP-DES in patients with CAD based on promising results in recent landmark trials, such as BIOFLOW V and BIOSTEMI. The aim of the present review article was to discuss the history of stent technology and the continued opportunities for improvements, focusing on the potential benefits of Orsiro BP-DES.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"13 2","pages":"17-24"},"PeriodicalIF":1.9,"publicationDate":"2019-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559229/pdf/heart-int-13-17.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40663809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterising the Clinical Spectrum, Diagnosis and Outcomes in Secondary Stress Cardiomyopathy. 继发性应激性心肌病的临床特征、诊断和预后。

IF 0.2

Heart International Pub Date : 2019-12-16 eCollection Date: 2019-01-01 DOI: 10.17925/HI.2019.13.2.26

Puneet Gupta, Anand Chockalingam

{"title":"Characterising the Clinical Spectrum, Diagnosis and Outcomes in Secondary Stress Cardiomyopathy.","authors":"Puneet Gupta, Anand Chockalingam","doi":"10.17925/HI.2019.13.2.26","DOIUrl":"https://doi.org/10.17925/HI.2019.13.2.26","url":null,"abstract":"Introduction: Available literature on takotsubo cardiomyopathy excludes critically ill patients due to challenges in angiographic confirmation. Secondary stress cardiomyopathy (sSC) occurs in patients already hospitalised for other critical illnesses. Diagnosis of sSC is challenging, while clinical presentation and outcomes are significantly different from primary stress cardiomyopathy. Our aim was to better characterise the clinical picture of sSC.Methods: The diagnosis of sSC was confirmed based on characteristic clinical and morphological features, applying our diagnostic algorithm suited for critically ill patients. We were able to characterise these sSC patients and differentiate their presentation from takotsubo registry population. Data on selected patients was extracted manually on Microsoft Excel worksheets with relevant patient demographics, presenting features and outcomes.Results: We developed a profile of sSC based on 18 consecutive confirmed cases diagnosed at our university hospital between April 2016 and September 2018. sSC differed from takotsubo cardiomyopathy in several key clinical aspects - younger people may develop sSC (range 21-86 years) and men were more frequently affected in comparison to takotsubo cardiomyopathy (29%). Dyspnoea was noted in 22% of our patients and angina was rare. Apical ballooning occurred in only 33% of the patients, while mid (39%) and basal left ventricular (11%) variants accounted for half of the patients. Mortality was much higher (28%) due to underlying medical comorbidities.Conclusions: Our series illustrates significant clinical and morphologic differences in the presentation of sSC. Shifting the emphasis to serial echocardiography would reduce the need for invasive catheterisation and downstream comorbidity in critical care settings.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"13 2","pages":"26-30"},"PeriodicalIF":0.2,"publicationDate":"2019-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559225/pdf/heart-int-13-26.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40651557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0